Days af­ter flag­ging its $773M takeover bid, Zymeworks mi­nor­i­ty share­hold­er adds As­traZeneca on­col­o­gy vet to the crew

The in­vest­ment firm that launched an un­so­licit­ed takeover bid for Zymeworks has now brought in an As­traZeneca vet to help de­vise the fu­ture strat­e­gy — adding some heft to its $773 mil­lion of­fer.

Alan Barge, the for­mer head of on­col­o­gy at As­traZeneca, is join­ing All Blue Cap­i­tal as an on­col­o­gy drug de­vel­op­ment ad­vi­sor.

“I have worked close­ly with the team in de­vel­op­ing a busi­ness plan for Zymeworks that can cre­ate su­pe­ri­or val­ue,” Barge said in a state­ment. “I look for­ward to con­tribut­ing my ex­per­tise to help put Zymeworks back on track.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER